Drug General Information
Drug ID	D0M5PH
Former ID	DNCL002909
Drug Name	PF-04937319
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 2	[523774]
Company	Pfizer
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Glucokinase	Target Info	Modulator	[533212]
KEGG Pathway	Glycolysis / Gluconeogenesis
	Galactose metabolism
	Starch and sucrose metabolism
	Amino sugar and nucleotide sugar metabolism
	Butirosin and neomycin biosynthesis
	Metabolic pathways
	Biosynthesis of antibiotics
	Carbon metabolism
	Insulin signaling pathway
	Insulin secretion
	Prolactin signaling pathway
	Glucagon signaling pathway
	Type II diabetes mellitus
	Maturity onset diabetes of the young
	Central carbon metabolism in cancer
Pathway Interaction Database	FOXA2 and FOXA3 transcription factor networks
	HIF-1-alpha transcription factor network
PathWhiz Pathway	Nucleotide Sugars Metabolism
	Starch and Sucrose Metabolism
	Galactose Metabolism
	Trehalose Degradation
Reactome	Regulation of gene expression in beta cells
	Glucose transport
	Glycolysis
WikiPathways	SIDS Susceptibility Pathways
	Glycolysis and Gluconeogenesis
	MAPK Signaling Pathway
	Regulation of beta-cell development
	Metabolism of carbohydrates
	Hexose transport
References
Ref 523774	ClinicalTrials.gov (NCT01517373) Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin. U.S. National Institutes of Health.
Ref 533212	Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.